adjuvant therapy

Phase 3Small molecule

adjuvant therapy is one of 205 small molecule programs targeting Gastroesophageal Junction Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

204

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastroesophageal Junction AdenocarcinomaActive, not recruiting

Nasopharyngeal CarcinomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Breast CancerActive, not recruiting

MelanomaActive, not recruiting

Prostate CancerActive, not recruiting

Endometrial CancerActive, not recruiting

Gastroesophageal Junction AdenocarcinomaPhase 2

Active, not recruiting

Nasopharyngeal CarcinomaPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

MelanomaPhase 3

Active, not recruiting

Prostate CancerPhase 3

Active, not recruiting

Endometrial CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

adjuvant therapy

FFudan University

Phase 3

1 2

Tecentriq

Roche

Preclinical

36 3

Zolymbus

AbbVie

Preclinical

1 4

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 5

Motexafin Gadolinium

PPharmacyclics LLC.

Preclinical

1 6

Dextromethorphan Hydrobromide

Boehringer Ingelheim

Preclinical

1 7

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

1 8

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 9

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 10

Bisphosphonate

Amgen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Not yet recruiting

Gastroesophageal Junction Adenocarcinoma

NCT06766578

Q3 2028

Phase 2Not yet recruiting

Non-Small Cell Lung Cancer

NCT07089199

Q4 2028

Phase 2Active, not recruiting

Breast Cancer

NCT04567420

Q4 2029

Phase 2Recruiting

Nasopharyngeal Carcinoma

NCT07067268

Clinical

Trials by Indication[1]

Endometrial Cancer1 trial

Predictors of Recurrence for High Risk Endometrial Cancer Patients

Completed·FFar Eastern Memorial Hospital··NCT04412902·92 enrolled

Prostate Cancer1 trial

Luteinizing Hormone-Releasing Hormone Agonist Therapy and Iodine I 125 Implant in Treating Patients With Previously Untreated Prostate Cancer

Completed·TTranslational Research Center for Medical Innovation, Kobe, Hyogo, Japan·Phase 3·NCT00664456·421 enrolled

Melanoma1 trial

Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients

Recruiting·PPhilogen S.p.A.·Phase 3·NCT03567889·186 enrolled

Nasopharyngeal Carcinoma1 trial

Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy

Recruiting·FFudan University·Phase 2·NCT07067268·76 enrolled

Gastroesophageal Junction Adenocarcinoma1 trial

Clinical Study of Low-dose Interval Radiotherapy Combined With Tirelizumab and SOX Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Not yet recruiting·SShandong Provincial Hospital·Phase 2·NCT06766578·32 enrolled

3 more indications

Non-Small Cell Lung Cancer1 trial

Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer(TitAN) : A Prospective, Single-Arm, Phase II Study

Not yet recruiting·QQilu Hospital of Shandong University·Phase 2·NCT07089199·34 enrolled

Rectal Cancer1 trial

Factors Predicting Recurrence in Rectal Cancer After Surgery

Completed·Aammar houssem··NCT03899870·188 enrolled

Breast Cancer1 trial

A Randomized, Phase II Trial of Circulating Tumor DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)

Active, not recruiting·CCriterium, Inc.·Phase 2·NCT04567420·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for adjuvant therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — adjuvant therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for adjuvant therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fudan University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FFudan University

adjuvant therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q3 2028

Q4 2028

Q4 2029

Trials by Indication[1]

Endometrial Cancer1 trial

Prostate Cancer1 trial

Melanoma1 trial

Nasopharyngeal Carcinoma1 trial

Gastroesophageal Junction Adenocarcinoma1 trial

Non-Small Cell Lung Cancer1 trial

Rectal Cancer1 trial

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News